Brought to you by 
Metuchen takes US, Canadian license to Vivus' Stendra
07 Oct 2016
Executive Summary
Metuchen Pharmaceuticals LLC licensed exclusive commercialization rights in the US, Canada, South America, and India to Vivus Inc.'s Stendra (avanafil)--an oral phosphodiesterase-5 inhibitor with a rapid onset of action for erectile dysfunction--which was approved in the US in 2012 and in Europe (where it's known as Spedra) in 2013.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Metuchen takes US, Canadian license to Vivus' Stendra
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice